These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Factors predisposing to ventricular tachyarrhythmia leading to appropriate ICD intervention in patients with coronary artery disease or non-ischaemic dilated cardiomyopathy. Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B Kardiol Pol; 2012; 70(12):1264-75. PubMed ID: 23264245 [TBL] [Abstract][Full Text] [Related]
11. Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure: systematic review and economic evaluation. Colquitt JL; Mendes D; Clegg AJ; Harris P; Cooper K; Picot J; Bryant J Health Technol Assess; 2014 Aug; 18(56):1-560. PubMed ID: 25169727 [TBL] [Abstract][Full Text] [Related]
12. A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context. Buxton M; Caine N; Chase D; Connelly D; Grace A; Jackson C; Parkes J; Sharples L Health Technol Assess; 2006 Aug; 10(27):iii-iv, ix-xi, 1-164. PubMed ID: 16904046 [TBL] [Abstract][Full Text] [Related]
13. Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial. Kuck KH; Schaumann A; Eckardt L; Willems S; Ventura R; Delacrétaz E; Pitschner HF; Kautzner J; Schumacher B; Hansen PS; Lancet; 2010 Jan; 375(9708):31-40. PubMed ID: 20109864 [TBL] [Abstract][Full Text] [Related]
14. Appropriate Shocks and Mortality in Patients With Versus Without Diabetes With Prophylactic Implantable Cardioverter Defibrillators. Junttila MJ; Pelli A; Kenttä TV; Friede T; Willems R; Bergau L; Malik M; Vandenberk B; Vos MA; Schmidt G; Merkely B; Lubinski A; Svetlosak M; Braunschweig F; Harden M; Zabel M; Huikuri HV; Sticherling C; Diabetes Care; 2020 Jan; 43(1):196-200. PubMed ID: 31645407 [TBL] [Abstract][Full Text] [Related]
16. Association between prophylactic implantable cardioverter-defibrillators and survival in patients with left ventricular ejection fraction between 30% and 35%. Al-Khatib SM; Hellkamp AS; Fonarow GC; Mark DB; Curtis LH; Hernandez AF; Anstrom KJ; Peterson ED; Sanders GD; Al-Khalidi HR; Hammill BG; Heidenreich PA; Hammill SC JAMA; 2014 Jun; 311(21):2209-15. PubMed ID: 24893088 [TBL] [Abstract][Full Text] [Related]
17. Introducing ICD-resistant mortality as an end point to evaluate the clinical efficacy of an implantable cardioverter-defibrillator in ischaemic cardiomyopathy. Floré V; Vandenberk B; Belmans A; Garweg C; Ector J; Willems R Acta Cardiol; 2018 Feb; 73(1):19-27. PubMed ID: 28685657 [TBL] [Abstract][Full Text] [Related]
18. Prophylactic Use of Implantable Cardioverter-Defibrillators in the Prevention of Sudden Cardiac Death in Dialysis Patients. Jukema JW; Timal RJ; Rotmans JI; Hensen LCR; Buiten MS; de Bie MK; Putter H; Zwinderman AH; van Erven L; Krol-van Straaten MJ; Hommes N; Gabreëls B; van Dorp W; van Dam B; Herzog CA; Schalij MJ; Rabelink TJ; Circulation; 2019 Jun; 139(23):2628-2638. PubMed ID: 30882234 [TBL] [Abstract][Full Text] [Related]